Market Overview
The global gene panel market size was valued at USD 1,153.2 Million in 2024 and is projected to reach USD 3,775.0 Million by 2033, exhibiting a CAGR of 14.08% during the forecast period of 2025-2033. This growth is driven by advances in precision medicine, rising prevalence of genetic disorders, and increasing adoption of next-generation sequencing technologies. The market offers expanding opportunities in personalized cancer therapies and early hereditary disease detection.
Study Assumption Years
• Base Year: 2024
• Historical Year/Period: 2019-2024
• Forecast Year/Period: 2025-2033
Gene Panel Market Key Takeaways
• The global gene panel market was valued at USD 1,153.2 Million in 2024.
• It is expected to grow at a CAGR of 14.08% from 2025 to 2033.
• The market forecast anticipates reaching USD 3,775.0 Million by 2033.
• North America dominated the market with a share of over 36.9% in 2024, driven by robust healthcare infrastructure and genomic research investments.
• Advancements in precision medicine and increased prevalence of genetic disorders are key market drivers.
• Rising adoption of next-generation sequencing and growing demand for personalized cancer therapies propel market expansion.
Sample Request Link:
https://www.imarcgroup.com/gene-panel-market/requestsample
Market Growth Factors
Factors such as genetic disorders increasing, precision medicine and next-generation sequencing (NGS) technologies adopting more often, personalized cancer treatment demanding more, and a focus growing regarding early diagnosis of hereditary diseases are expected to drive the growth of the global gene panel testing market. The decreasing costs of genetic testing and growing adoption in oncology, pharmacogenomics, and rare diseases research encourage growth.
The increasing prevalence of genetic diseases and cancer worldwide is additionally expected to drive the growth of the market. Genetic diseases and congenital disabilities account for 2-5% of all live births, leading to an increased demand for gene panels. As clinicians seek efficient diagnostic solutions for understanding a genetic predisposition for cancer and other conditions, gene panels are being adopted internationally.
The growing number of predesigned and customized gene panel tests, along with the decreasing laboratory infrastructure requirements of direct-to-consumer genetic testing kits, is expected to drive the market growth. Increasing research and development spending by biopharmaceutical and biotechnology companies to develop targeted cancer therapies is anticipated to drive the market growth by personalizing treatment with the help of actionable genetic biomarkers. Emerging applications are pre-gestational, prenatal and neonatal screenings, eased by existing nationwide government screening programs and recent advances in technology.
Market Segmentation
By Products and Services:
• Test Kits: Largest segment in 2024 with around 60.5% market share; valued for ease of use, accuracy, and growing clinical adoption.
• Testing Services: Present as a segment, but specific data not detailed.
By Technique:
• Amplicon-based Approach: Leading technique with approximately 79.2% market share in 2024 due to high efficiency and cost-effectiveness.
• Hybridization-based Approach: Recognized technique, data not detailed.
By Design:
• Predesigned Gene Panel: Market leader with about 66.5% share in 2024.
• Customized Gene Panel: Recognized segment, data not detailed.
By Application:
• Cancer Risk Assessment: Largest application segment with around 54.7% share in 2024.
• Diagnosis of Congenital Diseases
• Pharmacogenetics
• Others
By End User:
• Academic and Research Institutes: Leading segment with approximately 42.8% market share in 2024.
• Hospital and Diagnostic Laboratories
• Pharmaceutical and Biotechnology Companies
Regional Insights
North America dominates the global gene panel market with over 36.9% market share in 2024. This leadership is supported by advanced healthcare infrastructure, widespread adoption of NGS technologies, and significant investments in genomic research. The United States alone accounts for 75.90% of the North American market share, driven by high genetic disease prevalence and strong funding for genomic initiatives.
Recent Developments & News
• February 2024: Roche Diagnostics unveiled an enhanced hereditary cancer gene panel with over 100 genes.
• April 2024: Twist Bioscience launched a service for rapid design and ordering of customized gene panels.
• December 2023: Qiagen introduced a neurological disease-focused gene panel.
• April 2023: Agilent Technologies introduced an NGS assay for somatic variant profiling in solid tumors.
• May 2023: Unipath Specialty Laboratory launched the HRD Gene Panel in India using SOPHiA GENETICS technology.
Key Players
• Agilent Technologies Inc.
• BGI Genomics Co. Ltd. (BGI Group)
• Eurofins Scientific SE
• F. Hoffmann-La Roche AG
• Genewiz LLC (Azenta Inc.)
• Illumina Inc.
• Integrated DNA Technologies Inc. (Danaher Corporation)
• Novogene Co. Ltd.
• Qiagen N.V.
• Thermo Fisher Scientific Inc.
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
Request For Customization: https://www.imarcgroup.com/request?type=report&id=8105&flag=E
About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services, including market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals, branding, marketing and sales strategies, competitive benchmarking, pricing and cost research, and procurement research.
Contact Us
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No: (D) +91 120 433 0800
United States: +1-201971-6302
Comments (0)